
|Videos|September 10, 2019
Optimal Management of Early-Stage HCC
Advertisement
Key Takeaways:
The importance of multidisciplinary management of the underlying liver disease and function as well as the tumor burden in patients with hepatocellular carcinoma (HCC).
Solidifying interactions among locoregional practitioners, interventional radiologists, medical oncologists, and hepatologists to help define when to cease TACE (transarterial chemoembolization) and start a patient on systemic therapy.
Triggers to discontinue locoregional therapy and move to systemic therapy.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
FDA Accepts NDA for Zanzalintinib Plus Atezolizumab in Pretreated mCRC
2
Retrospective, Real-World Analysis Shows Improved OS With Apalutamide Over Darolutamide in mCSPC
3
HPV Vaccination and Evolving Screening Strategies Continue to Shape Cervical Cancer Prevention Efforts
4
SC Daratumumab Plus VRd Expands Options in Newly Diagnosed, Transplant-Ineligible Myeloma
5



































